Policy & Regulation
FlowMetric Diagnostics expands testing services to include serological antibody testing for SARS-CoV-2
22 May 2020 -

FlowMetric Diagnostics Inc, a subsidiary of FlowMetric Life Sciences Inc, is expanding testing services to include validated serological antibody testing for SARS-CoV-2 (COVID-19) exposure, it was reported on Thursday.

The company is collaborating with corporations, hospital networks, and municipalities to provide serological testing for their employees in response to the continued fight against the SARS-CoV-2 virus. These groups are interested in providing their employees with serological screening for the presence of anti-SARS-CoV-2 antibodies and supporting an organisation's 'return to work' strategy.

Renold J Capocasale, the founder and CEO of FlowMetric, said, 'Consistent with FlowMetric's focus on quality and compliance within FDA guidelines, we have completed a comprehensive validation of the anti-SARS-CoV-2 Immunoglobulin assay on an ELISA platform. For the past ten years, we have been at the forefront of interrogating the immune system as part of our Contract Research Organisation services supporting major pharmaceutical and biotech corporations, so this new assay is a natural extension of our scientific expertise.'